Impact Factor
4.30
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.65
1,700 total citations
h5-index
52
h5 depth signal
Cited share
91.8%
246 of 268
Total citations
1,700
Citation footprint
Metric signal
7.23
External metric anchor
Self-citation
0.5%
8 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
801
Italy
94
United Kingdom
89
France
62
Canada
61
Citing Fields of Research
Oncology
509
Immunology
180
Breast Cancer
134
Palliative Care
109
Hematology
94
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,583
Articles tracked across the journal lifetime
Indexed publication set
268
246 cited publications
Last 12 months
122
10.2 publications/month
Open access share
45.9%
56 OA publications in the last year
Leading citing country
United States
801 citing publications
Leading citing field
Oncology
509 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Sept. 1999-
v1n1, Sept. 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Immunology
Prostate Cancer
Lung Cancer
Musculoskeletal & Nerve Cancer
Breast Cancer
Broad Categories
Neoplasms
Urology
Prostate Cancer
Immunology
Lymphomas
Palliative Care
Breast Cancer
Brain Imaging
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s11912-026-01844-w
Open DOI
Antibody–Drug Conjugates in Biliary Tract Cancer: Current Evidence, Emerging Targets, and Future Directions
02
DOI 10.1007/s11912-026-01843-x
Open DOI
Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: Non-Invasive Assessment Across the Continuum
Purpose of Review Clinically significant portal hypertension (CSPH) is a key determinant of surgical candidacy, locoregional therapy safety, and systemic treatment outcomes in hepatocellular carcinoma (HCC), yet its non-invasive assessme...
03
DOI 10.1007/s11912-026-01842-y
Open DOI
Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers
Purpose of Review: Pancreatic ductal adenocarcinoma remains among the deadliest malignancies worldwide, and effective therapies are still lacking. Actinomycetota are among the richest microbial sources of bioactive secondary metabolites,...
04
DOI 10.1007/s11912-026-01841-z
Open DOI
Minoxidil and Prostaglandin Analogs for Chemotherapy-Induced Alopecia: A Scoping Review
05
DOI 10.1007/s11912-026-01840-0
Open DOI
Translating the Crosstalk Between Unfolded Protein Response and Ferroptosis to Cancer Therapies
06
07
DOI 10.1007/s11912-026-01831-1
Open DOI
Targeting the Epigenetic–Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions
Purpose of Review Acute myeloid leukemia (AML) exemplifies how malignant transformation can be driven by both epigenetic deregulation and genetic mutation. Aberrant DNA methylation, histone modifications, and chromatin remodelling cooper...
08
DOI 10.1007/s11912-026-01837-9
Open DOI
Unraveling the Mechanisms of Chemoresistance in Gastric Cancer: Insights and Emerging Research Strategies
09
10
DOI 10.1007/s11912-026-01828-w
Open DOI
Next-Generation Sequencing in Translational Sarcoma Research: Biological Insights and Emerging Directions
Purpose of Review: Sarcomas are rare and heterogeneous malignancies for which molecular diagnostics increasingly complement histopathology, immunohistochemistry, FISH, and RT-PCR. This review summarizes the main research applications of ...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 10, no. 2 (Mar. 2008)
Also issued online.